(Q37972673)

26 August 2017

Diabetes, cancer, and metformin: connections of metabolism and cell proliferation (English)

1 reference

26 August 2017

1 reference

2

Derek LeRoith

1 reference

26 August 2017

Emily Jane Gallagher

1

1 reference

PubMed ID

22211893

26 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

Annals of the New York Academy of Sciences

26 August 2017

1 reference

26 August 2017

1243

1 reference

26 August 2017

54-68

1 reference

Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes mellitus and risk of bladder cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes and risk of bladder cancer: evidence from a case-control study in New England

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes mellitus and risk of breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes mellitus and risk of prostate cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

An extended Myc network contributes to glucose homeostasis in cancer and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Associations between adipokines and obesity-related cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

A prospective study of plasma C-peptide and colorectal cancer risk in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin-like growth factor-I and cancer mortality in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Elevated insulin receptor content in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin receptor expression by human prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

AMPK phosphorylation of raptor mediates a metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

FOXOs, cancer and regulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Involvement of the Akt/PKB signaling pathway with disease processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metabolic status rather than cell cycle signals control quiescence entry and exit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Cancer cell metabolism: Warburg and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Prospective study of hyperglycemia and cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Mitochondria in cancer: not just innocent bystanders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

GLUT1 glucose transporter expression in benign and malignant thyroid nodules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Over-expression of facilitative glucose transporter genes in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Glucose uptake in the human gastric cancer cell line, MKN28, is increased by insulin stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin regulates GLUT1-mediated glucose transport in MG-63 human osteosarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

TIGAR, a p53-inducible regulator of glycolysis and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

c-Myc transactivation of LDH-A: implications for tumor metabolism and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

The interplay between MYC and HIF in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Dual effects of weight and weight gain on breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and -β via the IGF-1 and the insulin receptors in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Caloric restriction delays disease onset and mortality in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin and cancer occurrence in insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin suppresses glucose-6-phosphatase expression by a complex I inhibition and AMPK activation-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Insulin-lowering effects of metformin in women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Metabolic syndrome and endometrial cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06285.X

10.1111/J.1749-6632.2011.06285.X

21 January 2018

Identifiers

DOI

1 reference

release_urjsiajdrfegtnud6456dm7iue

26 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/urjsiajdrfegtnud6456dm7iue

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22211893

1 reference

PubMed ID

22211893